Metabolic-associated steatohepatitis (MASH) happens when excess fat in the liver causes inflammation and scarring, or fibrosis. The condition is serious, and when left untreated it can lead to ...

Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero confirmed its status as a key ...

Roche has scooped up 89bio and its phase III FGF21 analogue pegozafermin, as drug developers continue to race to advance new drugs for the liver disease metabolic dysfunction-associated ...

Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the most prevalent obesity related comorbidities Akero Therapeutics’s FGF21 ...

The second edition of the Mash Ball, held at The St. Regis Mumbai on October 5, 2025, unfolded as a glittering celebration of art, fashion, and social impact. Conceptualised by Shalini Passi, founder ...

If developing drugs for metabolic dysfunction-associated steatohepatitis (MASH) were a poker game, you could say Novo Nordisk (NASDAQ Copenhagen: NOVO-B) saw a competitor’s bet and raised the stakes ...

Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...

Screenshot of PathAI's AIM-MASH AI Assist in action. An artificial intelligence model developed by PathAI – used to help diagnose metabolic dysfunction associated steatohepatitis (MASH) from liver ...

There's nothing nicer than tucking into a warm and hearty comfort meal on a cold night - and Rick Stein's ultimate dish is perfect for those types of evenings. Sausages and mash is a true British ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Several noninvasive tests (NITs) used in patients with metabolic dysfunction-associated steatohepatitis (MASH) treated with semaglutide for 72 weeks showed significant reductions in relevant ...